NCT05011097View on ClinicalTrials.gov

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

October 23, 2023

Study Completion Date

June 25, 2024

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

Y150

Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.

Trial Locations (2)

Unknown

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Wuhan YZY Biopharma Co., Ltd.

INDUSTRY